ARGA Investment Management LP Decreases Holdings in Merck & Co., Inc. $MRK

Key Points

• ARGA Investment Management LP reduced its Merck stake by 15.5% in the first quarter, selling 45,951 shares and leaving it with 251,458 shares valued at about $30.2 million.
• Merck reported better-than-expected quarterly results, with EPS of -$1.28 versus the expected -$1.47 and revenue of $16.29 billion topping estimates. The company also maintained FY 2026 EPS guidance of 5.04 to 5.16.
• The stock has recent support from both dividend income and analyst optimism, including a $0.85 quarterly dividend and multiple Buy ratings with a consensus target price of $132.72. Recent FDA approval news for KEYTRUDA in bladder cancer could also support future growth.

ARGA Investment Management LP cut its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 15.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 251,458 shares of the company's stock after selling 45,951 shares during the quarter. Merck & Co., Inc. comprises about 1.0% of ARGA Investment Management LP's investment portfolio, making the stock its 25th biggest position. ARGA Investment Management LP's holdings in Merck & Co., Inc. were worth $30,248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock valued at $26,770,014,000 after acquiring an additional 2,185,853 shares in the last quarter. State Street Corp grew its holdings in Merck & Co., Inc. by 1.6% during the 4th quarter. State Street Corp now owns 120,040,168 shares of the company's stock valued at $12,737,504,000 after purchasing an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP increased its stake in Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after buying an additional 11,156,354 shares during the period. Geode Capital Management LLC lifted its holdings in Merck & Co., Inc. by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock worth $6,307,572,000 after buying an additional 249,110 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in Merck & Co., Inc. by 0.8% in the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company's stock worth $4,731,018,000 after buying an additional 359,486 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Down 1.1%

Shares of Merck & Co., Inc. stock opened at $123.72 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The firm has a market cap of $305.56 billion, a P/E ratio of 34.85, a P/E/G ratio of 2.68 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29. The business has a 50-day moving average price of $118.83 and a 200 day moving average price of $116.28.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts' consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.'s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were paid a dividend of $0.85 per share. The ex-dividend date was Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 2.7%. Merck & Co., Inc.'s dividend payout ratio (DPR) is 95.77%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MRK. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a "neutral" rating and a $125.00 target price for the company. UBS Group lifted their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a report on Monday, April 13th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday. Morgan Stanley raised their price target on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an "equal weight" rating in a research report on Thursday. Finally, Bank of America upped their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus target price of $132.72.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.